Nicotinic acetylcholine receptors (nAChR) are widely expressed in non-neuronal tissue, but data about their expression in vascular tissue are rare. To study the expression of nAChR α4, α7 and β2 in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) in human arteries of smokers and non-smokers, arteriae thoracicae internae dissected for coronary artery bypass grafting were analysed immunhistochemically and by polymerase chain reaction (PCR). ECs of the tunica intima and the vasa vasorum as well as the VSMCs of the tunica media showed clear staining for nAChR α4, α7 and β2, without significant differences between non-smokers and smokers in all vascular layers. Further verification of nAChR α4, α7 and β2 expression of whole-tissue homogenates using PCR analysis showed no differences in the subtype expression between non-smokers and smokers. This provides an important basis for further investigations using positron electron tomography (PET) tracers for imaging of nAChRs in vascular health and disease.
Introduction
Nicotinic acetylcholine receptors (nAChR) are a family of ligand-gated ion channels, which exhibit Na + , K + and Ca 2+ permeability and consist of 17 distinct isoforms of five subunits (α1-α10, β1-β4, γ, δ and ε). The subunits can assemble as homogeneous or heterogeneous pentamers in many possible combinations. Beside their well-known expression in the nervous system and at motor endplates, nAChRs are widely distributed in non-neuronal mammalian cells including endothelial cells (ECs), vascular smooth muscle cells (VSMCs), bronchial epithelial cells, keratinocytes, immune cells and cancer cells [1] [2] [3] [4] . 28.3 ± 0.7 26.8 ± 0.9 % diabetes mellitus (n) 57.1 (8) 23.1 (3) % hypertension (n) 92.9 (13) 92.3 (12) % heart failure (n) 28.6 (4) 30.8 (4) Data are represented as mean ± S.E.M. Footnote: * p=0.01
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A number of nAChR subunits are expressed in ECs (α3, α5, α7, α10, β2, β and β4) and VSCMs (α2, α3, α4, α5, α7, α10) of blood vessels, whereas the most abundant receptor subunit is α7 [5] . α7-nAChRs on the plasma membrane of VSMCs and ECs are responsible for the nicotine response of these cells, which is characterized by stimulated proliferation and migration of ECs and increased release of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) as well as for pro-angiogenic processes [6] . NAChRs in VSMCs have been shown to be involved in pathological processes [7] [8] [9] . They mediate the nicotine-induced migration, inhibit apoptosis and stimulate proliferation of human aortic smooth muscle cells, at least via an increased expression of the platelet-derived growth factor (PDGF). It was speculated that these processes contribute to the development and progression of atherosclerosis [8] . All these findings emphasize the pivotal role of vascular nAChRs in normal intercellular communication, proliferation, invasion and angiogenesis.
However, systematic and detailed information about subunits of nAChRs, along with their incidence and distribution in the human vascular system is lacking. Therefore, the aim of this study was to investigate and quantify the abundance of nAChR subunits in human arteries, especially on ECs and VSMCs. Furthermore, we investigated whether there is a difference in the expression in the arteries of non-smokers and smokers.
Materials and methods

Study population und sample collection
The study was approved by the local ethical board and performed according to the declaration of Helsinki. All patients gave written informed consent. Twenty-seven patients undergoing elective cardiac surgery for coronary artery bypass grafting were included in this study. Samples of arteriae thoracicae internae were collected from patients undergoing bypass surgery and either paraffin-embedded (n=17) or snap-frozen for ribonucleic acid (RNA) extraction (n=10).
RNA extraction and reverse transcriptase PCR analysis
Snap frozen tissue specimen was homogenized in TRIzol® (Life Technologies GmbH, Darmstadt, Germany).
RNA was extracted following the manufacturers protocol. 2 µg RNA were reverse transcribed using 0.5 µg Oligo(dT) primer (Promega, Mannheim, Germany), 1 mM dNTPs, 10x reaction buffer, 4 U Omniscript® reverse transcriptase (Qiagen, Hilden, Deutschland) and 10 U RiboLock RNase Inhibitor (Thermo Scientific, Schwerte, Germany). 2 µl of cDNA was amplified by adding 1 U Platinum® Taq Polymerase (Life Technologies GmbH), 10x reaction buffer, 1.5 mM magnesium chloride, 0.2 mM desoxy-nucleotides (dNTPs) and 0.2 µM specific forward (fw) and reverse (rev) primer (nAChRα4: fw 5'-cgaccagcagaactgcacca-3', rev 5'-agcaggaagacggtgagcga-3'; nAChRα7: fw 5'-tgtggccgcatggcctgctc-3', rev 5'-ctttggacacggcctccacg-3'; nAChRβ2: fw 5'-ggcgagaagatgacgttgtg-3', rev 5'-gttgacgaagcacgtgcagg-3'; glyceraldehyde 3-phosphate dehydrogenase (GAPDH): fw 5'-tcgtggaaggactcatgacc-3', rev 5'-ccttgcccacagccttggca-3'). PCR products were separated on a 1% agarose gel and visualized using ethidium bromide.
Immunohistochemistry
Tissue specimen were fixed with 4% formalin and embedded in paraffin. Paraffin sections were stained using the following primary antibodies: nAchR subunit 4, 7 or 2 (1:50, respectively, all Santa Cruz Biotechnolgies, Santa Cruz, CA). After washing, the signal was amplified and visualized using the EnVisionTM FLEX System and 3,3′-diaminobenzidine (DAB) staining according to the manufacturer's instructions (Dako). A counterstaining with haemalaun was also performed. Sections without primary antibody served as negative, sections of neonatal rat brain as positive controls. Analysis was performed using a Zeiss microscope and AxioVision software (Carl Zeiss Microscopy GmbH, Jena, Germany). DAB-stained areas were analysed using ImageJ software.
Statistics
Data are shown as mean ± standard error of the mean (S.E.M). Statistical analysis was performed with Student´s t-test using SigmaStat software (Jandel Scientific, San Rafael, CA, USA). A p-value ≤0.05 was considered to be significant.
Results
The study cohort did not show significant differences regarding age, body mass index and for the frequencies of diabetes mellitus, hypertension and heart failure in the two study groups 'smokers' and 'non-smokers' ( Table 1 ). The distribution of gender was significantly different (p=0.01) between both study groups: the group 'smokers' consisted solely of male patients.
Immunohistochemical analysis of nAChR α4, α7 and β2 subunits was analysed in the different vascular layers (endothelium, VSMCs in the tunica media, in adventitial cells and ECs of the vasa vasorum) and did not show apparent differences regarding the staining intensity between the internal mammary arteries of non-smokers and smokers (Figure 1) . Analysis of the endothelium showed that the nAChRs containing the 4-subunit were expressed as a lower percentage (non-smokers: 68.3% ± 7.4%, smokers: 51.0% ± 12.6%) compared to nAChRs containing 7 (non-smokers: 85.2% ± 3.8%, smokers: 79.0% ± 8.0%) or β2 (non-smokers: 77.4% ± 9.4%, smokers: 67.6% ± 13.3%) (Figure 2A) . The relative stained area of VSMCs exhibited a similar expression of nAChR subunits. The 4-subunit (non-smokers: 3.8% ± 0.9%, smokers: 2.5% ± 0.6%) was expressed at a lower level than 7-subunit (non-smokers: 12.6% ± 2.7%, smokers: 12.1% ± 3.4%) or 2 (non-smokers: 13.0% ± 2.3%, smokers: 14.2% ± 2.9%) ( Figure 2B ). However, no significant differences could be detected in the average percentages of nAChR α4, α7 and β2 immunostained endothelium as well as in stained areas of VSMCs of the tunica media. In accordance with the immunohistochemical results, reverse transcriptase PCR (RT-PCR) analysis revealed that the mRNA-expression of nAChR subunits α4, α7 and β2 of the arteriae thoracicae internae did not differ between smokers and non-smokers (Figure 3 ).
Discussion
The results of this study demonstrated an abundance of nAChR α4, α7 and β2 subunits in the endothelium and in VSMCs of the tunica media in human arteriae thoracicae internae. The expression of nAChRs in non-neuronal cells such as ECs and VSMCs was reported in previous in vitro studies [10, 11] . It has been reported that the nAChR α4 subunit is expressed in human umbilical vein ECs and in human microvascular ECs in vitro [12, 13] . Duerrschmidt and colleagues [12] investigated the intercellular communication of umbilical vein ECs and stated that nAChRs play a role in the impairment of intercellular communication. According to their results, this process is mediated through α4β2 and α3β2 receptors but not α7 nAChRs. A further study showed that α7-containing nAChRs play a role in the cardiovascular system and act as an important protector in myocardial ischemia, reperfusion injury, stroke, atherosclerosis and hypertension [14] .
Our study is one of the few reports that confirm the in vivo expression of nAChRs on human vascular tissue. Our study showed that α4 and α7 is present in ECs and VSMCs of smaller human arteries such as arteriae thoracicae internae. Furthermore, the expression was quantified and the results demonstrated that the 4 subunit was expressed to a lower extend in ECs as well as in VSMCs compared to α7 or 2 subunit. Scientific reports indicate reverse results on expression of nAChR subunits in vascular tissue. Regarding the α4, α7 and 2 subunits, a recent study proved the expression of α4 and α7 on VSMCs and of α7 and 2 for aortic ECs in humans [15] . Our data are in accordance with in vitro results of human primary cultures of ECs by Wang et al., who reported the expression of almost all nAChR subunits in ECs [5] . Furthermore, they report that the most abundant receptor subunit is α7 nAChRs. Presumably, differences exist between in vitro-analyses (e.g. primary cells, cell lines) and in vivo-studies of tissue samples as well as of the different vessel types (e.g. aorta, arteriae) and vessel layers (tunica intima, media and adventitia). Therefore, it is reasonable that a clear separation of in vitro and in vivo results as well as those obtained in different species and vessel types are necessary to generate an expression map of nAChRs in the vascular system. Furthermore, this study revealed, that there is no significant difference in the expression of the three investigated nAChR subunits in non-smokers and smokers, neither in ECs, nor in the VSMCs of the tunica media. In general, the effect of nicotine as a major component of cigarette smoke on the cells of the vascular system is very complex. For example, in vitro studies with cigarette smoke extract causes apoptosis of aortic VSCMs and aortic ECs in humans and rodent animals [6] . In contrast, it has been reported that nicotine inhibits apoptosis of aortic VSMCs and ECs through nAChRs [7] . Several studies have shown that nicotine stimulates the proliferation and migration of ECs, increase VEGF and FGF release by vascular VSMCs and ECs and promote angiogenesis. In turn, angiogenesis is regulated by VEGF receptor-and α7 nAChR-mediated pathways [6] . Although nicotine as exogenous agonist of nicotinic acetylcholine receptors in the vasculature is studied very well, clinical data on receptor expression under chronic nicotine exposure are rare. In addition, it has to be stated that nicotine is one of the major and well-studied components of cigarette smoke, but it is one of 4000 other ingredients [16] .
The actual correlations between chronic nicotine exposure and the distribution and changes of nAChRs in the vascular system in vivo have to be clarified in further studies. A very promising starting point for studying nAChRs in vivo is the usage of nAChR analogs in imaging systems. Bucerius et al. [17] evaluated a radiolabeled nAChR ligand for in vivo positron emission tomography (PET) imaging in humans, and quantified the uptake in the ascending and descending aorta, the aortic arch and the carotids. Although, these studies are designed to detect arterial disease and pathological changes in the vascular system, important insights can be generated about the distribution of nAChRs from these in vivo studies.
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